MicroRNA-155 regulates casein kinase 1 gamma 2: a potential pathogenetic role in chronic lymphocytic leukemia

por Zhang, T, Davidson-Moncada, J K, Mukherjee, P, Furman, R R, Bhavsar, E, Chen, Z, Hakimpour, P, Papavasiliou, N, Tam, W
Publicado 2017

P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG C...

por Wang, M., Mei, M., Barr, P. M., Barrientos, J., de Vos, S., Furman, R., Patel, K., Thompson, P. A., Choi, M., Kallam, A., Zhu, Y., Chakraborty, S., Marinello, P., Spurgeon, S. E.
Publicado 2022

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study

por Montillo, M, O'Brien, S, Tedeschi, A, Byrd, J C, Dearden, C, Gill, D, Brown, J R, Barrientos, J C, Mulligan, S P, Furman, R R, Cymbalista, F, Plascencia, C, Chang, S, Hsu, E, James, D F, Hillmen, P
Publicado 2017

P1130: ACALABRUTINIB IN TREATMENT-NAIVE OR RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: 5-YEAR FOLLOW-UP OF A PHASE 2, SINGLE-ARM STUDY

por Owen, R., McCarthy, H., Rule, S., D’Sa, S., Thomas, S., Tournilhac, O., Forconi, F., José Kersten, M., Luigi Zinzani, P., Iyengar, S., Kothari, J., Minnema, M., Kastritis, E., Cheson, B., Walter, H., Greewald, D., Calvo, R., Wun, C.-C., Furman, R.
Publicado 2022

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

por Brown, J R, Hillmen, P, O’Brien, S, Barrientos, J C, Reddy, N M, Coutre, S E, Tam, C S, Mulligan, S P, Jaeger, U, Barr, P M, Furman, R R, Kipps, T J, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, J M, Munir, T, Burger, J A, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, D F, Byrd, J C
Publicado 2018